

# Treatment Strategies for Co-Occurring ADHD and Substance Use Disorders

John J. Mariani, MD, Frances R. Levin, MD

New York State Psychiatric Institute, New York, New York;  
Division on Substance Abuse, Columbia University College of Physicians and Surgeons, New York, New York

*Attention-deficit hyperactivity disorder (ADHD) is a common co-occurring mental disorder among patients with substance use disorders (SUD). Clinicians must be cognizant of the complicated nature of diagnosis and treatment of ADHD when comorbid with SUD. Pharmacotherapy remains the mainstay of treatment for ADHD, although complementary psychotherapeutic approaches have been developed. Psychostimulant medications are the most commonly used medications to treat ADHD, but many clinicians are reluctant to prescribe stimulants to patients with SUD. Recommendations for treatment planning and clinical management for patients with co-occurring ADHD and SUD are discussed. (Am J Addict 2007;16:45–56)*

## LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to:

- Identify typical challenges in clinical diagnosis of ADHD in adults with co-occurring SUD.
- Explain how different types of ADHD pharmacotherapies affect the risks of SUD in specific patient types.
- Distinguish between primary symptoms and substance-induced symptoms in ADHD patients with SUD.
- Discuss the advantages and disadvantages of non-stimulant medications in patients with ADHD and co-occurring SUD, including second-line medications.

- Describe treatment scenarios in ADHD that are most likely to lead to SUD, exacerbate ongoing SUD, or minimize risks of SUD.
- Provide an overview of psychosocial treatments for ADHD and co-occurring SUD that can help optimize long-term treatment effectiveness.

## INTRODUCTION

Attention-deficit hyperactivity disorder (ADHD) is a syndrome characterized by persistent patterns of inattention and/or impulsivity and hyperactivity that is inappropriate for a given age or developmental stage. ADHD is the most common mental disorder in childhood,<sup>1</sup> with an estimated prevalence in the United States of 5–10%.<sup>2,3</sup> It is estimated that up to 60% of childhood cases of ADHD will continue to have clinically significant symptoms of ADHD as adults,<sup>4–7</sup> and the prevalence of adult ADHD in the United States is estimated to be 2–5%.<sup>8–11</sup> ADHD symptoms result in a large individual and public burden; it is estimated that consequences of ADHD result in the loss of 120 million days of annual lost work in the U.S. labor force, which is equivalent to \$19.5 billion lost human capital.<sup>12</sup>

Large-scale epidemiologic surveys in the United States have reported that substance use disorders are associated with increased rates of comorbid psychiatric disorders,<sup>9,13–16</sup> including mood, psychotic, anxiety, personality, and other classes of disorders. While it is clear that substance use disorders are associated with increased rates of comorbid psychiatric disorders as compared to the general population, the converse is true as well: individuals with substance-independent psychiatric disorders are at an increased risk of having a substance use disorder. The Epidemiologic Catchment Area Survey<sup>13</sup> reported that among individuals with any lifetime mental disorder diagnosis, 28.9% had a lifetime substance use disorder, as compared to a rate of 13.2% for those respondents who had no history of a mental disorder.

Received August 29, 2006; revised September 20, 2006; accepted September 28, 2006.

Dr. Levin has current or past research support from Ortho-McNeil Pharmaceuticals, Eli Lilly & Company, Shire, AstraZeneca, and UCB Pharma, and serves or has served as a consultant to Shire Pharmaceuticals, AstraZeneca, Ortho-McNeil Pharmaceuticals, and Cephalon/Alkermes.

Address correspondence to Dr. Mariani, 1051 Riverside Drive, Unit 66, New York, New York 10032. E-mail: jm2330@columbia.edu.

The ECA found that having a lifetime history of any mental disorder was associated with more than twice the risk of having an alcohol disorder and more than four times the risk of having a drug use disorder.

The association of ADHD and SUD has become an increasing focus of investigation over the past decade. Studies of clinical samples of individuals with SUD seeking treatment have demonstrated that ADHD is a common co-occurring mental disorder,<sup>17–19</sup> although historically, community-based studies have not included adult ADHD among the disorders surveyed.<sup>13,14,16</sup> However, the recently published National Comorbidity Survey Replication (NCS-R) included ADHD in its survey and estimated the prevalence of adult ADHD to be 4.4%.<sup>8</sup> With regards to the rate of co-occurrence of ADHD and SUD, the NCS-R found that 15.2% of individuals with adult ADHD met DSM-IV criteria for a SUD, as compared to 5.6% of individuals without ADHD, resulting in a significant odds ratio of 3.0.<sup>8</sup> Complimentary to these findings, the NCS-R found that among individuals with SUD, 10.8% met criteria for adult ADHD, as compared to a prevalence of 3.8% in individuals without SUD.

The rates of ADHD co-occurrence in studies of treatment-seeking clinical samples of individuals with SUD are higher than the community-based NCS-R, with the reported prevalence of adult ADHD ranging from 10–24%.<sup>17–19</sup> In addition, it is estimated that more than 25% of substance-abusing adolescents meet diagnostic criteria for ADHD.<sup>20–22</sup> This disparity in rates of co-occurring ADHD and substance use disorders between community-based and clinical studies is likely due to Berkson's bias,<sup>23</sup> which is the phenomenon that patients in clinical treatment settings are more likely to exhibit a higher degree of association between two disorders. A practical outcome of this phenomenon is that clinicians in SUD treatment settings will frequently encounter co-occurring ADHD.

While the exact cause of ADHD is unknown, the available evidence supports the theory that dopamine neurotransmission dysfunction is at least partly responsible for the characteristic symptoms of ADHD. Evidence supporting dopamine involvement in ADHD symptomatology includes pharmacotherapy studies, which show that stimulant medications that increase dopamine levels effectively treat ADHD symptoms,<sup>24–27</sup> genetic studies, which have linked dopamine genes to ADHD,<sup>28–30</sup> and imaging studies, which have shown abnormalities of dopamine function and structural abnormalities in regions of the brain with concentrations of dopamine-producing neurons.<sup>31–33</sup> The therapeutic effects of psychostimulants on ADHD symptoms are thought to be due to their ability to increase extracellular dopamine,<sup>34,35</sup> particularly in the striatum.<sup>36</sup> Volkow and Swanson<sup>37</sup> have postulated that psychostimulant-induced extracellular dopamine release in the striatum improves attention by the enhancement of task-related neuronal cell firing.

As the development of SUD is also linked to dopamine,<sup>38</sup> there may be common factors that lead to the development of ADHD and co-occurring SUD. By definition, ADHD is present before the age of 7, and SUDs often develop during adolescence and early adulthood, so it is likely that the increased association of ADHD and SUD is the product of a developmental interaction with ADHD symptoms (eg, impulsivity or behavior dysregulation) and the consequences of ADHD (eg, poor academic performance), creating an increased opportunity for the development of a SUD. Emerging evidence suggests that psychostimulant treatment of ADHD during childhood reduces the likelihood of developing a SUD,<sup>39</sup> although the exact mechanism of this risk reduction is not known. The risk of initiation of substance use in adolescents is related more to symptom severity (eg, aggression or impulsivity) than the status of meeting criteria for ADHD,<sup>40</sup> suggesting that the risk of SUD development in adolescents with ADHD is dimensional, rather than categorical. In adolescents, the severity of attentional symptoms may be a more important risk factor than behavioral symptoms.<sup>41</sup>

Given the common co-occurrence of ADHD with SUD, clinicians working with patients with SUD must be proficient in the identification and treatment of ADHD. Due to the evolving understanding of the clinical manifestations of adult ADHD<sup>42</sup> and the relatively recent recognition of the elevated risk of ADHD among adults with SUD,<sup>8</sup> clinicians working with SUD patients are often unfamiliar with the assessment and management of ADHD. Further, because the primary treatment for ADHD is stimulant pharmacotherapy, which has an inherent abuse potential, the treatment of ADHD in patients with SUD is both complex and controversial. This article discusses treatment planning and clinical management of patients with co-occurring ADHD and SUD.

## DIAGNOSING ADHD IN PATIENTS WITH SUD

The diagnosis of ADHD in children and adults remains a clinical diagnosis—there are no neuropsychiatric or laboratory tests that alone have been shown to have clinical utility in diagnosing ADHD. In adults, the clinical diagnosis of ADHD remains challenging, particularly in patients with co-occurring SUD, as there is a lack of consensus on diagnostic criteria,<sup>42</sup> symptoms overlap with other psychiatric disorders, and there is a need for a retrospective diagnosis of childhood ADHD. The criteria for ADHD in the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-IV-TR)<sup>43</sup> were developed for diagnosing ADHD in children and are currently used for adults as well, although the validity of the criteria set is debated.<sup>42</sup>

Diagnosing ADHD in patients who are actively using substances or who recently initiated abstinence is challenging. Substances of abuse have many acute and chronic

effects that mimic the symptoms of psychiatric disorders, including ADHD. For example, the use of stimulants can lead to changes in attentional capacity and activity level both during intoxication and recovery, and chronic marijuana use may lead to deficits in attention. In addition, many patients are unable to describe recent periods of abstinence from substance use, making the distinction between primary and substance-induced symptoms difficult.

While some authorities recommend evaluating patients after a period of prolonged abstinence,<sup>44</sup> this is not possible in many cases. Often a careful clinical history of symptoms during past periods of abstinence or prior to the onset of substance use problems is the best available method to assess whether inattention and hyperactivity symptoms represent a primary disorder or are substance-induced. Symptoms that occur during periods of active substance use are difficult to interpret, because if they occur exclusively in the context of active substance use, a diagnosis of ADHD is inappropriate. Furthermore, in adults, the clinical diagnosis of ADHD remains challenging, because there is a lack of consensus on diagnostic criteria, particularly regarding the requirement that symptoms be present prior to the age of 7.<sup>42</sup> However, because retrospective diagnoses of childhood ADHD in adults made on the basis of self-report tend to overdiagnose ADHD,<sup>45</sup> a conservative approach must be maintained. A practical approach when working with adults with a SUD might be to consider ADHD likely if symptoms can be recalled as having been present since early adolescence, but unlikely if the symptoms appeared simultaneously or subsequently to the development of the SUD. Collateral information from family or review of objective data (eg, school performance reports) can be very useful in determining whether symptoms were present during childhood.

While the diagnosis of ADHD is ultimately clinically-based, there are structured instruments and interviews that can assist in the evaluation of a patient for ADHD. A comprehensive diagnostic battery, such as might be employed in a research setting, would include, in addition to a comprehensive psychiatric interview, the Structured Clinical Interview for DSM-IV (SCID)<sup>46</sup> and the Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID),<sup>47</sup> which systematically assesses adults for both childhood and adult symptoms. However, in many clinical settings, performing a SCID and CAADID is not feasible. A more practical approach is to use a semi-structured clinical interview using the DSM-IV TR criteria for ADHD as a guide (ie, review symptoms in criteria set with patient). The ADHD Rating Scale-IV<sup>48</sup> and the DSM-IV SNAP checklist<sup>49</sup> can also be useful in screening for ADHD symptoms. In any setting, it is essential to gather data from other informants (eg, partner, parent, or close friend) to better understand the nature and severity of the symptoms and their impact on the patient's functioning.

## IMPACT OF ADHD ON SUD TREATMENT

Given the ongoing controversy over the diagnostic criteria for ADHD in adults and the complicated clinical issue of using ADHD pharmacotherapy in patients with SUD, a reasonable starting point in discussing treatment strategies is to ask, How important is it to treat ADHD in patients with SUD? An initial approach this question is to consider the impact of ADHD on individuals who do not have SUD. Adults with ADHD have less educational attainment, increased dismissals from their jobs, more traffic accidents and car license suspensions, more psychosocial problems with social deficits, and a greater frequency of divorce.<sup>12,50</sup> The next step is to consider the evidence that ADHD affects the development and course of substance use disorders: individuals with substance use disorders and ADHD have an earlier onset of substance abuse than those without ADHD, a greater likelihood of having continuous problem if they develop substance dependence, a reduced likelihood of going into remission, and a tendency to take longer to reach remission.<sup>51</sup> Despite having more treatment exposure, individuals who have ADHD seem to do less well with SUD treatment,<sup>51,52</sup> although this may reflect that individuals with more severe symptoms are more likely to receive SUD treatment. Also, both adolescents and adults are less likely to progress well in treatment or remain in treatment.<sup>53-55</sup> Therefore, the diagnosis and treatment of ADHD in patients with SUD seems to be essential to achieve the best possible clinical outcome.

## PHARMACOTHERAPY FOR ADHD IN PATIENTS WITH SUDs

The most commonly used pharmacotherapies for childhood ADHD are two psychostimulants, methylphenidate and analogs of amphetamine. In turn, methylphenidate and amphetamine analogs have been the most widely studied pharmacotherapies in adult ADHD, although non-stimulant medications, including tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs), bupropion, monoamine oxidase inhibitors, atypical antipsychotics, clonidine, atomoxetine, and venlafaxine have been studied as well. Modafinil, a novel wake-promoting agent that is chemically and pharmacologically distinct from other psychostimulants, has also been investigated as a potential treatment for ADHD.

### Stimulant Medications

Amphetamine is a potent CNS stimulant of which the effects are thought to be due to the stimulation of the cortex and the reticular activating system.<sup>56</sup> Amphetamine's mechanism of action is primarily due to promoting dopamine release, although it blocks dopamine reuptake as well. Amphetamine analogs, a first-line treatment for childhood ADHD, have also been shown to be effective for the

treatment of ADHD in adults.<sup>57</sup> In the United States, amphetamine analogs are used primarily for ADHD and also for narcolepsy. Commercially available amphetamine analogs include methamphetamine, dextroamphetamine, and mixed amphetamine salts (MAS). Methamphetamine is available only as an immediate release preparation and is rarely used due to abuse and diversion concerns. Dextroamphetamine is available in immediate and sustained release preparations. MAS is a fixed-combination amphetamine composed of equal amounts of dextroamphetamine saccharate, dextroamphetamine sulfate, racemic amphetamine aspartate monohydrate, and racemic amphetamine sulfate. It is available in immediate and sustained release preparations. Side effects most commonly associated with amphetamine administration include insomnia, emotional lability, nausea/vomiting, nervousness, palpitations, elevated blood pressure, and rapid heart rate. Rare, but serious adverse effects include severe hypertension, seizures, psychosis, and myocardial infarction.

Methylphenidate is a classical psychostimulant widely used in the United States for the treatment of ADHD. Methylphenidate is a piperidine derivative that is structurally related to amphetamine.<sup>56</sup> The mechanism of action of methylphenidate is primarily due to blocking dopamine reuptake in the striatum. Methylphenidate has been one of the first-line treatments for ADHD in children for decades and has been demonstrated to be effective for the treatment of ADHD in adults.<sup>58</sup> Methylphenidate is available in multiple immediate and sustained release preparations, using a variety of strategies for delaying absorption. The most common side effects of methylphenidate are insomnia, nervousness, tachycardia, and hypertension. As with amphetamines, rare but serious adverse effects include severe hypertension, seizures, psychosis, and myocardial infarction.

### *Abuse Potential of Psychostimulants*

Methylphenidate and amphetamine analogs are widely used in the treatment of ADHD; however, concern exists with respect to their abuse potential, particularly in patients with SUD. The phenomenon of nonmedical use of stimulant medications has been documented in large-scale survey studies; according to the National Survey on Drug Use and Health (NSDUH), 8.8% of Americans aged 12 years or older reported having used prescription-type stimulants non-medically at least once in their lifetime.<sup>59</sup> Therefore, the risks of using these potentially abusable medications in a vulnerable population must be considered carefully.

There is a limited body of laboratory and clinical evidence to consider when assessing the risks of using stimulant medications in patients with SUD. In a laboratory double-blind choice procedure, individuals with ADHD significantly chose methylphenidate over placebo,<sup>60</sup> while other measures of abuse potential were not elevated. In laboratory studies of patients with<sup>61</sup> and without<sup>62</sup> SUD,

both methylphenidate and amphetamine analogs demonstrate characteristics associated with abuse potential. Methamphetamine, which is a commonly abused substance,<sup>59</sup> has been shown to be a positive reinforcer (ie, individuals exposed to the substance are likely to choose to be exposed again) in humans,<sup>63</sup> providing further evidence for its abuse potential. In contrast to the data described above, a laboratory study of methylphenidate in cocaine-dependent patients receiving treatment did not increase cocaine craving nor ratings associated with abuse potential,<sup>64</sup> suggesting that the context of use, in this case therapeutic, may influence subjective effects and abuse potential.<sup>37</sup> Because the reinforcing effects of stimulants are associated with rapid changes in serum concentrations<sup>37</sup> and sustained-release preparations of methylphenidate (which slow the rate of onset of the drug's effect) are associated with less stimulant-like drug effects (eg, increased ratings of "good effects") in healthy volunteers,<sup>65,66</sup> it is likely that delayed-release stimulant preparations have lower abuse potential than immediate-release stimulant preparations. An additional characteristic of delayed-release preparations that make diversion and abuse less likely is that they are more difficult to use via a non-oral route (eg, injected or insufflated intranasally).

The use of stimulants and non-stimulant medications has been studied in patients with co-occurring adult ADHD and SUD. Methylphenidate has been shown to be effective in uncontrolled trials in reducing ADHD symptoms and cocaine use.<sup>67,68</sup> A three-arm double-blind placebo-controlled trial of bupropion and methylphenidate for the treatment of ADHD in cocaine-dependent patients receiving methadone maintenance treatment for opioid dependence found no benefit of bupropion or methylphenidate on ADHD symptoms or cocaine use outcomes.<sup>69</sup> A double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence found that methylphenidate improved ADHD symptoms on some measures but not others, and it did not show a reduction in cocaine use.<sup>26</sup> Consistent with this, Levin et al.<sup>70</sup> found that sustained-release methylphenidate did not demonstrate an improvement in cocaine use in cocaine-dependent individuals with ADHD. An uncontrolled trial of bupropion for the treatment of cocaine dependence and adult ADHD in 11 patients reported that ADHD and cocaine use symptoms decreased significantly.<sup>71</sup> In none of the trials using stimulants was abuse of prescribed stimulant medication reported.

Additionally, psychostimulants, including amphetamine analogs, methylphenidate, and modafinil, have been studied for the treatment of cocaine dependence. The results of these studies have been mixed with regard to the effects on cocaine use outcomes, with the most consistent effects reported for dextroamphetamine.<sup>72,73</sup> Dextroamphetamine has also been studied for the substitution treatment of amphetamine dependence<sup>74,75</sup> and this approach has been found to be feasible. Despite concerns that psychostimulants use may

lead to increased craving and cocaine use, this has not been reported in controlled clinical trials.<sup>26,69,70,72,73,76</sup>

In summary, while stimulants are clearly diverted for nonmedical use, clinical data suggest that the use of delayed-release preparation and the context of therapeutic risk may reduce the potential for abuse.

### Nonstimulant Medications

Nonstimulant pharmacotherapies for ADHD include a heterogeneous group of medications, which with the exception of atomoxetine are off-label and typically considered second line treatments. However, there are certain instances where non-stimulant medications would be considered first line, such as if a motor tic disorder is present or in the case of cardiovascular disease.

Atomoxetine is a recently FDA-approved nonstimulant agent for the treatment of ADHD in children, adolescents, and adults. Atomoxetine is a noradrenergic reuptake inhibitor with efficacy for treating the symptoms of ADHD.<sup>77,78</sup> The effects of atomoxetine are more gradual than those experienced with stimulant medications. Common side effects of atomoxetine include sedations, appetite suppression, nausea, vomiting, and headache. Rare but serious side effects reported in children and adolescents include increased suicidal ideation and hepatotoxicity. Atomoxetine has no known abuse potential, so it is an attractive candidate medication for study in the treatment of ADHD in patients with substance use disorders, though published studies are presently lacking.

The antidepressants are off-label and considered second-line treatments for ADHD. Tricyclic antidepressants, which block the reuptake of norepinephrine in addition to other neurotransmitters, have some efficacy in reducing ADHD symptoms, but are considered less effective than the stimulant medications.<sup>79</sup> The dopaminergic antidepressant bupropion has been reported to be effective in the treatment of ADHD,<sup>80–82</sup> although when studied in patients with SUD, it offered no benefit over placebo.<sup>69</sup> Venlafaxine, a norepinephrine-serotonin reuptake inhibitor antidepressant medication, has limited evidence of efficacy in ADHD in uncontrolled clinical trials.<sup>83,84</sup> Monoamine oxidase inhibitors have been shown to have efficacy for ADHD, but the potential for hypertensive crises associated with tyramine-containing foods and medications (both illicit and prescribed) limit their utility, and should be considered contraindicated in patients with SUD.

Clonidine, a noradrenergic alpha-2 agonist antihypertensive agent, is effective for the treatment of ADHD, particularly among adolescents with hyperactivity and aggressiveness.<sup>85</sup> Side effects include sedation, dry mouth, depression, confusion, electrocardiographic changes, and hypertension with abrupt withdrawal. Guanfacine, also a norepinephrine alpha-2 agonist, has limited evidence supporting its efficacy as a treatment for ADHD.<sup>86</sup>

Modafinil, a novel wake-promoting agent that is FDA-approved for narcolepsy and shift work sleep, has recently been shown to be effective for the treatment of ADHD in children and adolescents,<sup>87–89</sup> and more limited evidence suggests that it may be effective for adult ADHD as well.<sup>90</sup> Because there is limited evidence that modafinil may have potential as a treatment for cocaine dependence,<sup>91</sup> it is deserving of further study in the treatment of co-occurring ADHD and SUD. Although modafinil has some stimulant-like properties (eg, promoting wakefulness), it has minimal abuse potential, so for the purposes of discussion it is being grouped with non-stimulants.

### Choice of Pharmacotherapy for Co-Occurring ADHD and SUD

The treatment of adult ADHD in patients with SUD has been controversial, as the primary pharmacotherapy for ADHD is psychostimulants and, historically, there has been reluctance on the part of clinicians to use these medications in patients with addictive disorders. However, although non-stimulant medications have been shown to have efficacy for ADHD, these agents have not been demonstrated to have comparable efficacy to the psychostimulants.<sup>92</sup> Some authorities<sup>93,94</sup> have proposed approaches that emphasize medications with a lower risk of abuse, such as antidepressants or clonidine, before using traditional stimulant medications such as methylphenidate or amphetamine analogs. However, clinical trials of methylphenidate<sup>26,67,70,95</sup> and dextroamphetamine<sup>72–74,76</sup> for the treatment of either cocaine dependence or ADHD in patients with co-occurring SUD have shown that stimulant medications can be used safely in patients with SUD and have a relatively low risk of abuse under monitored conditions.

While the treatment literature for ADHD in patients with SUD is not well developed, the emerging trend is that medications effective for adult ADHD may be effective for adults with ADHD and co-occurring SUD, but the therapeutic benefit may be less or non-existent if substance use is ongoing.<sup>82</sup> Several possible causes of this phenomenon include the following:

- patients with ongoing SUD do not reliably take their medication,
- patients with SUD may require higher doses (ie, higher tolerance) than administered in clinical trials, and
- ongoing SUD makes detection of a therapeutic effect less likely.<sup>70</sup>

As in children, the available evidence supports the use of stimulant medications over non-stimulant medications for adult ADHD, although direct comparisons are lacking. While stimulant medications, such as methylphenidate and amphetamine analogs, have the potential for abuse, which is a heightened clinical concern in patients

with comorbid SUD, the available evidence suggests that this risk is relatively low under monitored conditions, such as in clinical trials. However, it should be expected that a proportion of patients with ADHD comorbid with SUD will misuse, abuse, or divert stimulant medications,<sup>96-98</sup> particularly in less structured treatment settings. A related clinical concern, that stimulant treatment would worsen SUD outcomes, has not been observed in clinical trials, and in children, stimulant treatment of ADHD has been associated with reduced risk of developing SUD.<sup>39</sup>

The primary approach to the treatment of ADHD remains pharmacotherapy; thus, a rational treatment plan for a patient with ADHD co-occurring with SUD will most likely include pharmacotherapy. For patients without SUD, stimulant medications are the first line treatment choice; however, given the risk of misuse and diversion of stimulant pharmacotherapy, which may be heightened in patients with SUD, the decision to use stimulant medications must be undertaken carefully. In some cases, nonstimulant pharmacotherapy would be more a more desirable alternative. The decision to use stimulant pharmacotherapy in a patient with ADHD and co-occurring SUD requires an individualized risk-benefit assessment.

The assessment of risk in using stimulant pharmacotherapy in a patient with SUD is a broad consideration of the patient's clinical condition, past history, and overall functional status. A conservative approach for treating co-occurring ADHD and SUD would be to begin treatment with a non-stimulant pharmacotherapy, but if an adequate response is not obtained, stimulant pharmacotherapy should be considered. While this approach would minimize the risk of diversion and the misuse of stimulants, given that nonstimulants do not appear to have equivalent efficacy to stimulants, this increased assurance in terms of misuse may come at the expense of ADHD symptom response. The available evidence does not support differing degrees of risk based on type of SUD (eg, cannabis dependence vs. cocaine dependence) or even current substance use, because, as discussed previously, stimulant pharmacotherapy has been used successfully in patients with active cocaine dependence.<sup>26,67,69,70,72-74,76,95</sup> Perhaps the only absolute contraindication to stimulant pharmacotherapy in a patient with SUD would be current abuse of prescription stimulants or a clear indication that the patient would sell or divert their medication.

While it would be desirable to provide clear-cut recommendations or an algorithm (eg, when patient has characteristic X, give drug Y), the data are lacking to provide such guidance. Instead, clinicians must consider all of the available clinical information and make the best initial decision, with the understanding that the treatment plan may need to be modified over time. The known efficacy of psychostimulants must be balanced against the risk of diversion or misuse, and although this risk is likely heightened in patients with SUD, it likely varies

considerably between patients, and needs to be assessed clinically rather than be defined categorically. Factors such as ongoing substance use, prior history of misuse of stimulant medication, other co-occurring psychiatric disorders, and overall clinical stability should be taken into account. For a patient who is abstinent from substance use and has good social functioning, a trial of stimulant medication probably represents a low risk intervention, whereas if a patient is using substances or is otherwise clinically compromised, the use of stimulant pharmacotherapy must be approached more cautiously. The individualized risk assessment should also dictate other elements of clinical management, such as the frequency of office visits or urine toxicology testing.

When the decision to use stimulant pharmacotherapy is made, the choice of formulation should be considered carefully. Most clinicians experienced in the treatment of ADHD in patients with SUD would likely recommend the use of sustained-release preparations of stimulants to reduce the potential for misuse, although clinical data are lacking to support this approach. Novel delivery systems such as the crush-resistant shell of Concerta (Alza Corporation, Fort Washington, Pennsylvania, USA)<sup>99</sup> or the recently FDA-approved methylphenidate skin patch, are more resistant to abuse and may be desirable alternatives in patients with co-occurring ADHD and SUD.

A final consideration regarding choice of medication is that of combination pharmacotherapy. While there is very minimal data to guide choices with regard to combinations of ADHD pharmacotherapies, nonetheless, clinicians will often be faced with clinical situations that call for the consideration of combination pharmacotherapy. These clinical situations can broadly be categorized into four groups: partial response, dose-limiting side effects, associated disorders, and comorbid diagnoses. Potential approaches to these clinical situations include combinations of stimulants and non-stimulant medications, combinations of non-stimulant medications, and combinations of immediate- and delayed-action stimulants.

## **PSYCHOSOCIAL TREATMENTS FOR ADHD AND CO-OCCURRING SUD**

Although pharmacotherapy is the cornerstone of treatment for ADHD, a variety of psychosocial treatments can be employed in combination with medication to optimize the long-term management of this chronic disorder. Unfortunately, little controlled research has been undertaken on psychosocial treatments for adults with ADHD. Data on treatments for children are not likely to be directly relevant, given that those interventions typically emphasize parent training<sup>100</sup> and, in some cases, show no additive benefit of psychosocial treatment to patients receiving stimulant pharmacotherapy.<sup>101</sup>

An important element of the treatment of ADHD is psychoeducation. Having the patient learn about the

disorder and its pervasive effects on their functioning can help to set the stage for developing an effective therapeutic alliance. Providing educational literature or referrals to community education/support groups, such as Children and Adults with Attention Deficit Disorder (CHADD; <http://www.chadd.org>) or the Attention Deficit Disorder Association (ADDA; <http://www.add.org>), can be very useful for patients and families in gaining understanding about the disorder.

Cognitive behavioral therapy (CBT) has been shown to be effective in reducing symptoms of adult ADHD.<sup>102</sup> Modifications of CBT such as structured skills training<sup>103</sup> or cognitive remediation<sup>104</sup> have also been shown to be effective. However, in patients receiving CBT for SUD, there is evidence that cognitive deficits, such as those associated with ADHD, are associated with low treatment retention,<sup>105</sup> suggesting that retaining patients with cognitive deficits in CBT-based SUD treatment is difficult, and that individualized treatment strategies may need to be developed.

Additional behavioral strategies for ADHD that are used clinically but not studied in controlled trials in adults include coaching and behavior modification. Coaching is a collaborative relationship between the patient and a professional to develop strategies for managing problems such as procrastination, time-management, and organization. Behavior modification is a technique used mainly for children where desired behaviors are positively reinforced to increase their frequency.

## **CLINICAL MANAGEMENT OF ADHD CO-OCCURRING WITH SUD**

The management of patients with co-occurring ADHD and SUD requires a comprehensive approach to assessing symptom burden and functional impairment. The simultaneous treatment of both conditions is likely to be the optimal approach because ADHD symptoms (eg, impulsivity, poor planning) will interfere with SUD treatment, and substance use will limit the benefit of ADHD treatment.

When using psychostimulant pharmacotherapy for ADHD in patients with SUD, careful attention to the clinical frame and boundaries of treatment needs to be made. It should be discussed explicitly with the patient that the use of stimulant medication carries an inherent risk of misuse or abuse, and that if evidence of such developments, the appropriateness of stimulant use will be reconsidered. Emphasis should be placed on the adherence to the prescribed medication regimen, and that medication should not be taken on an “as needed” basis. It should be made clear to the patient, and ideally the family, that if it becomes apparent that prescribed stimulant medication is being misused, abused, or diverted, that there is no obligation on the part of the physician to continue treatment. Fortunately, stimulant medications can be discontinued abruptly without dangerous sequelae.

The use of psychostimulants in patients with substance use disorders requires careful monitoring, including urine toxicology testing. Relapse or worsening of substance use may necessitate re-assessing the appropriateness of stimulant pharmacotherapy. Careful documentation of all prescriptions must be maintained in order to monitor the amount and frequency of the drug being prescribed. Repetitive requests to replace “missing,” “lost,” or “stolen” medication should be cause for concern, as should similar requests for dose increases when not clinically supported. Delayed-release preparations are preferred to reduce the rate of change of drug blood levels, which is less reinforcing, as well as to discourage non-oral use. Patient visits should be frequent. Despite all mechanisms in place to reduce the risk of diversion, misuse, or abuse of stimulants, it should be expected that a small percentage of patients with ADHD comorbid with substance use disorders will do so, and that careful clinical monitoring will detect such nontherapeutic use early and minimize its adverse effects.

Rating scales, such as the Conners Adults Attention-Deficit Rating Scale,<sup>106</sup> can be useful for monitoring symptom severity over time in response to prolonged abstinence or ADHD pharmacotherapy. One important caveat is that ADHD rating scales administered to patients who have not yet achieved a prolonged period of abstinence will capture substance-induced symptoms of inattention and hyperactivity in addition to possible symptoms due to ADHD. In such cases, sequential rating scale administration over time can help resolve the diagnosis; substance-induced symptoms should improve with abstinence, whereas symptoms due to ADHD will be stable in the absence of treatment. Rating scales help provide benchmarks from which the efficacy of therapy can be measured, particularly if multiple trials of medications are required to achieve a clinical response.

Assessment for malingering is an important component of managing a patient with co-occurring ADHD and SUD, given that the mainstay of treatment for ADHD are stimulants that are potentially abusable. Because inattention symptoms tend to predominate in adults with ADHD and symptom assessment is almost entirely based on self-report, the potential for patients with substance use disorders attempting to mislead clinicians in an effort to obtain stimulants is always present. Efforts to obtain collateral data from family and other sources should be made, including childhood school records.

## **SUMMARY**

ADHD and SUDs frequently co-occur, particularly in SUD treatment settings. The etiology of the increased association of ADHD and SUD is unknown, although one possible cause is that substance use represents an attempt to “self-medicate” ADHD symptoms. Untreated ADHD leads to significant consequences and may impair a patient’s ability to benefit from SUD treatment.

Pharmacotherapy remains the mainstay for the treatment of ADHD, and psychostimulants continue to be first-line treatments. Several non-stimulant medications have shown promise for the treatment of ADHD, but their role for patients with co-occurring SUDs has not yet been determined. While stimulant medications have the potential for abuse and must be used cautiously in patients with substance use disorders, the available evidence suggests that stimulant medications administered under monitored conditions can be safe and effective in patients with substance use disorders. However, ongoing substance use can limit the efficacy of stimulant pharmacotherapy, and there is an irreducible risk of misuse, abuse, and diversion of stimulant medications when used to treat ADHD comorbid with substance use disorders. A conservative approach for treating co-occurring ADHD and SUD would be to begin treatment with a non-stimulant pharmacotherapy, but if an adequate response is not obtained, consider stimulant pharmacotherapy. The decision regarding the use of stimulant medications for a patient with ADHD and a co-occurring substance use disorder should be made on the basis of a broad clinical assessment and an individual risk-benefit analysis. For many patients, psychostimulants can be used safely and effectively; however, careful monitoring during treatment is essential to ensure prescribed stimulants are being used in a therapeutic manner, and in the case of worsening substance use or when faced with evidence of the diversion of prescribed medication, treatment should be discontinued.

Please turn to page 55–56 for the post-test and evaluation on this CME activity.

*Work on this manuscript was supported in part by grants K23 DA021209 (Dr. Mariani) and K02 DA00465 (Dr. Levin) from the National Institute on Drug Abuse, Bethesda, Md.*

## REFERENCES

1. Olfson M. Diagnosing mental disorders in office-based pediatric practice. *J Dev Behav Pediatr.* 1992;13:363–365.
2. Barbaresi WJ, Katusic SK, Colligan RC, et al. How common is attention-deficit/hyperactivity disorder? Incidence in a population-based birth cohort in Rochester, Minn. *Arch Pediatr Adolesc Med.* 2002;156:217–224.
3. Adler L, Cohen J. Diagnosis and evaluation of adults with attention-deficit/hyperactivity disorder. *Psychiatr Clin North Am.* 2004; 27:187–201.
4. Biederman J, Mick E, Faraone SV. Age-dependent decline of symptoms of attention deficit hyperactivity disorder: impact of remission definition and symptom type. *Am J Psychiatry.* 2000; 157:816–818.
5. Rasmussen P, Gillberg C. Natural outcome of ADHD with developmental coordination disorder at age 22 years: a controlled, longitudinal, community-based study. *J Am Acad Child Adolesc Psychiatry.* 2000;39:1424–1431.
6. Barkley RA, Fischer M, Smallish L, Fletcher K. The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. *J Abnorm Psychol.* 2002;111:279–289.
7. Kessler RC, Adler LA, Barkley R, et al. Patterns and predictors of attention-deficit/hyperactivity disorder persistence into adulthood: results from the national comorbidity survey replication. *Biol Psychiatry.* 2005;57:1442–1451.
8. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey Replication. *Am J Psychiatry.* 2006;163:716–723.
9. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Arch Gen Psychiatry.* 2005;62:617–627.
10. Weiss M, Murray C. Assessment and management of attention-deficit hyperactivity disorder in adults. *CMAJ.* 2003;168:715–722.
11. Murphy K, Barkley RA. Attention deficit hyperactivity disorder adults: comorbidities and adaptive impairments. *Compr Psychiatry.* 1996;37:393–401.
12. Kessler RC, Adler L, Ames M, et al. The prevalence and effects of adult attention deficit/hyperactivity disorder on work performance in a nationally representative sample of workers. *J Occup Environ Med.* 2005;47:565–572.
13. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA.* 1990;264: 2511–2518.
14. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. *Arch Gen Psychiatry.* 1994;51:8–19.
15. Grant BF, Harford TC. Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. *Drug Alcohol Depend.* 1995;39:197–206.
16. Grant BF, Stinson FS, Dawson DA, et al. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Arch Gen Psychiatry.* 2004; 61:807–816.
17. Levin FR, Evans SM, Kleber HD. Prevalence of adult attention-deficit hyperactivity disorder among cocaine abusers seeking treatment. *Drug Alcohol Depend.* 1998;52:15–25.
18. Clure C, Brady KT, Saladin ME, Johnson D, Waid R, Rittenbury M. Attention-deficit/hyperactivity disorder and substance use: symptom pattern and drug choice. *Am J Drug Alcohol Abuse.* 1999; 25:441–448.
19. Schubiner H, Tzelepis A, Milberger S, et al. Prevalence of attention-deficit/hyperactivity disorder and conduct disorder among substance abusers. *J Clin Psychiatry.* 2000;61:244–251.
20. Halikas JA, Meller J, Morse C, Lyttle MD. Predicting substance abuse in juvenile offenders: attention deficit disorder versus aggressivity. *Child Psychiatry Hum Dev.* 1990;21:49–55.
21. Thompson LL, Riggs PD, Mikulich SK, Crowley TJ. Contribution of ADHD symptoms to substance problems and delinquency in conduct-disordered adolescents. *J Abnorm Child Psychol.* 1996;24:325–347.
22. DeMilio L. Psychiatric syndromes in adolescent substance abusers. *Am J Psychiatry.* 1989;146:1212–1214.
23. Berkson J. Limitations of the application of fourfold table analyses to hospital data. *Biometrics Bulletin.* 1946;2:47–53.
24. Greenhill LL, Halperin JM, Abikoff H. Stimulant medications. *J Am Acad Child Adolesc Psychiatry.* 1999;38:503–512.
25. Shenker A. The mechanism of action of drugs used to treat attention-deficit hyperactivity disorder: focus on catecholamine receptor pharmacology. *Adv Pediatr.* 1992;39:337–382.
26. Schubiner H, Saules KK, Arken CL, et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. *Exp Clin Psychopharmacol.* 2002;10:286–294.



27. Greenhill LL, Swanson JM, Steinhoff K, et al. A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. *J Am Acad Child Adolesc Psychiatry*. 2003;42:1234–1241.
28. Ebstein RP, Nemanov L, Klotz I, Gritsenko I, Belmaker RH. Additional evidence for an association between the dopamine D4 receptor (D4DR) exon III repeat polymorphism and the human personality trait of Novelty Seeking. *Mol Psychiatry*. 1997;2:472–477.
29. LaHoste GJ, Swanson JM, Wigal SB, et al. Dopamine D4 receptor gene polymorphism is associated with attention deficit hyperactivity disorder. *Mol Psychiatry*. 1996;1:121–124.
30. Cook EH, Jr., Stein MA, Krasowski MD, et al. Association of attention-deficit disorder and the dopamine transporter gene. *Am J Hum Genet*. 1995;56:993–998.
31. Volkow ND, Wang GJ, Fowler JS, Ding YS. Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit/hyperactivity disorder. *Biol Psychiatry*. 2005;57:1410–1415.
32. Giedd JN, Blumenthal J, Molloy E, Castellanos FX. Brain imaging of attention deficit/hyperactivity disorder. *Ann NY Acad Sci*. 2001;931:33–49.
33. Bush G, Frazier JA, Rauch SL, et al. Anterior cingulate cortex dysfunction in attention-deficit/hyperactivity disorder revealed by fMRI and the Counting Stroop. *Biol Psychiatry*. 1999;45:1542–1552.
34. Solanto MV. Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. *Behav Brain Res*. 1998;94:127–152.
35. Volkow ND, Wang G, Fowler JS, et al. Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain. *J Neurosci*. 2001;21:RC121.
36. Kiyatkin EA, Rebec GV. Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. *J Neurophysiol*. 1996;75:142–153.
37. Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. *Am J Psychiatry*. 2003;160:1909–1918.
38. Kalivas PW, Volkow ND. The neural basis of addiction: a pathology of motivation and choice. *Am J Psychiatry*. 2005;162:1403–1413.
39. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. *Pediatrics*. 2003;111:179–185.
40. Ernst M, Luckenbaugh DA, Moolchan ET, et al. Behavioral predictors of substance-use initiation in adolescents with and without attention-deficit/hyperactivity disorder. *Pediatrics*. 2006;117:2030–2039.
41. Molina BS, Pelham WE, Jr. Childhood predictors of adolescent substance use in a longitudinal study of children with ADHD. *J Abnorm Psychol*. 2003;112:497–507.
42. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. *Am J Psychiatry*. 2004;161:1948–1956.
43. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*. Washington, DC: American Psychiatric Association; 2000.
44. Milin R, Loh E, Chow J, Wilson A. Assessment of symptoms of attention-deficit hyperactivity disorder in adults with substance use disorders. *Psychiatr Serv*. 1997;48:1378–1380,1395.
45. Mannuzza S, Klein RG, Klein DF, Bessler A, ShROUT P. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. *Am J Psychiatry*. 2002;159:1882–1888.
46. First MB, Spitzer RL, Gibbon M, Williams JBW. *Structured Clinical Interview for DSM-IV Axis I Disorders*. Patient ed., SCID-I/P, Version 2.0. New York: New York State Psychiatric Institute, Biometrics Research Department; 1995.
47. Conners CK, Erhardt JN, Epstein D, Parker JDA, Sitarenios G, Sparrow E. Self-rating of ADHD symptoms in adults: I. Factor structure and normative data. *J Atten Disord*. 1999;3:141–151.
48. DuPaul G. *ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretation*. New York, NY: Guilford Press; 1998.
49. Swanson J. *SNAP-IV Scale*. Irvine, Calif.: University of California Child Development Center; 1994.
50. Mannuzza S, Klein RG. Long-term prognosis in attention-deficit/hyperactivity disorder. *Child Adolesc Psychiatr Clin N Am*. 2000;9:711–726.
51. Wilens TE, Biederman J, Mick E. Does ADHD affect the course of substance abuse? Findings from a sample of adults with and without ADHD. *Am J Addict*. 1998;7:156–163.
52. Carroll KM, Rounsaville BJ. History and significance of childhood attention deficit disorder in treatment-seeking cocaine abusers. *Compr Psychiatry*. 1993;34:75–82.
53. Wise BK, Cuffe SP, Fischer T. Dual diagnosis and successful participation of adolescents in substance abuse treatment. *J Subst Abuse Treat*. 2001;21:161–165.
54. White AM, Jordan JD, Schroeder KM, et al. Predictors of relapse during treatment and treatment completion among marijuana-dependent adolescents in an intensive outpatient substance abuse program. *Subst Abuse*. 2004;25:53–59.
55. Levin FR, Evans SM, Vosburg SK, Horton T, Brooks D, Ng J. Impact of attention-deficit hyperactivity disorder and other psychopathology on treatment retention among cocaine abusers in a therapeutic community. *Addict Behav*. 2004;29:1875–1882.
56. Brunton LL, Lazo JS, Parker KL. *Goodman and Gilman's The Pharmacological Basis of Therapeutics*. New York: McGraw-Hill; 2006.
57. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. *Arch Gen Psychiatry*. 2001;58:775–782.
58. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 2004;24:24–29.
59. Substance Abuse and Mental Health Services Administration. *Results from the 2002 National Survey on Drug Use and Health: National Findings*. NHSDA Series H-22, DHHS Publication No. SMA 03-3836. Rockville, Md.: Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2003.
60. Fredericks EM, Kollins SH. Assessing methylphenidate preference in ADHD patients using a choice procedure. *Psychopharmacology (Berl)*. 2004;175:391–398.
61. Stoops WW, Glaser PE, Fillmore MT, Rush CR. Reinforcing, subject-rated, performance and physiological effects of methylphenidate and d-amphetamine in stimulant abusing humans. *J Psychopharmacol*. 2004;18:534–543.
62. Rush CR, Essman WD, Simpson CA, Baker RW. Reinforcing and subject-rated effects of methylphenidate and d-amphetamine in non-drug-abusing humans. *J Clin Psychopharmacol*. 2001;21:273–286.
63. Hart CL, Ward AS, Haney M, Foltin RW, Fischman MW. Methamphetamine self-administration by humans. *Psychopharmacology (Berl)*. 2001;157:75–81.
64. Roache JD, Grabowski J, Schmitz JM, Creson DL, Rhoades HM. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. *J Clin Psychopharmacol*. 2000;20:61–68.
65. Kollins SH, Rush CR, Pazzaglia PJ, Ali JA. Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate. *Exp Clin Psychopharmacol*. 1998;6:367–374.
66. Spencer TJ, Biederman J, Ciccone PE, et al. PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. *Am J Psychiatry*. 2006;163:387–395.
67. Levin FR, Evans SM, McDowell DM, Kleber HD. Methylphenidate treatment for cocaine abusers with adult attention-deficit/

- hyperactivity disorder: a pilot study. *J Clin Psychiatry*. 1998;59:300–305.
68. Somoza EC, Winhusen TM, Bridge TP, et al. An open-label pilot study of methylphenidate in the treatment of cocaine dependent patients with adult attention deficit/hyperactivity disorder. *J Addict Dis*. 2004;23:77–92.
69. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. *Drug Alcohol Depend*. 2006;81:137–148.
70. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. *Drug Alcohol Depend*. in press.
71. Levin FR, Evans SM, McDowell DM, Brooks DJ, Nunes E. Bupropion treatment for cocaine abuse and adult attention-deficit/hyperactivity disorder. *J Addict Dis*. 2002;21:1–16.
72. Grabowski J, Rhoades H, Schmitz J, et al. Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. *J Clin Psychopharmacol*. 2001;21:522–526.
73. Shearer J, Wodak A, van Beek I, Mattick RP, Lewis J. Pilot randomized double blind placebo-controlled study of dexamphetamine for cocaine dependence. *Addiction*. 2003;98:1137–1141.
74. Shearer J, Wodak A, Mattick RP, et al. Pilot randomized controlled study of dexamphetamine substitution for amphetamine dependence. *Addiction*. 2001;96:1289–1296.
75. White R. Dexamphetamine substitution in the treatment of amphetamine abuse: an initial investigation. *Addiction*. 2000;95:229–238.
76. Grabowski J, Rhoades H, Stotts A, et al. Agonist-like or antagonist-like treatment for cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. *Neuropsychopharmacology*. 2004;29:969–981.
77. Adler LA, Spencer TJ, Milton DR, Moore RJ, Michelson D. Long-term, open-label study of the safety and efficacy of atomoxetine in adults with attention-deficit/hyperactivity disorder: an interim analysis. *J Clin Psychiatry*. 2005;66:294–299.
78. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. *Biol Psychiatry*. 2003;53:112–120.
79. Wolraich ML, Wibbelsman CJ, Brown TE, et al. Attention-deficit/hyperactivity disorder among adolescents: a review of the diagnosis, treatment, and clinical implications. *Pediatrics*. 2005;115:1734–1746.
80. Conners CK, Casat CD, Gualtieri CT, et al. Bupropion hydrochloride in attention deficit disorder with hyperactivity. *J Am Acad Child Adolesc Psychiatry*. 1996;35:1314–1321.
81. Wilens TE, Spencer TJ, Biederman J, et al. A controlled clinical trial of bupropion for attention deficit hyperactivity disorder in adults. *Am J Psychiatry*. 2001;158:282–288.
82. Wilens TE, Haight BR, Horrigan JP, et al. Bupropion XL in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled study. *Biol Psychiatry*. 2005;57:793–801.
83. Motavalli Mukaddes N, Abali O. Venlafaxine in children and adolescents with attention deficit hyperactivity disorder. *Psychiatry Clin Neurosci*. 2004;58:92–95.
84. Olvera RL, Pliszka SR, Luh J, Tatum R. An open trial of venlafaxine in the treatment of attention-deficit/hyperactivity disorder in children and adolescents. *J Child Adolesc Psychopharmacol*. 1996;6:241–250.
85. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 1999;38:1551–1559.
86. Taylor FB, Russo J. Comparing guanfacine and dextroamphetamine for the treatment of adult attention-deficit/hyperactivity disorder. *J Clin Psychopharmacol*. 2001;21:223–228.
87. Biederman J, Swanson JM, Wigal SB, Boellner SW, Earl CQ, Lopez FA. A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, double-blind, and placebo-controlled study. *J Clin Psychiatry*. 2006;67:727–735.
88. Greenhill LL, Biederman J, Boellner SW, et al. A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. *J Am Acad Child Adolesc Psychiatry*. 2006;45:503–511.
89. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. *J Clin Psychiatry*. 2006;67:137–147.
90. Taylor FB, Russo J. Efficacy of modafinil compared to dextroamphetamine for the treatment of attention deficit hyperactivity disorder in adults. *J Child Adolesc Psychopharmacol*. 2000;10:311–320.
91. Dackis CA, Kampman KM, Lynch KG, Pettinati HM, O'Brien CP. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. *Neuropsychopharmacology*. 2005;30:205–211.
92. Biederman J, Spencer T, Wilens T. Evidence-based pharmacotherapy for attention-deficit hyperactivity disorder. *Int J Neuropsychopharmacol*. 2004;7:77–97.
93. Castaneda R, Levy R, Hardy M, Trujillo M. Long-acting stimulants for the treatment of attention-deficit disorder in cocaine-dependent adults. *Psychiatr Serv*. 2000;51:169–171.
94. Riggs PD. Clinical approach to treatment of ADHD in adolescents with substance use disorders and conduct disorder. *J Am Acad Child Adolesc Psychiatry*. 1998;37:331–332.
95. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A. Replacement medication for cocaine dependence: methylphenidate. *J Clin Psychopharmacol*. 1997;17:485–488.
96. Wilens TE, Gignac M, Swezey A, Monuteaux MC, Biederman J. Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications. *J Am Acad Child Adolesc Psychiatry*. 2006;45:408–414.
97. Gordon SM, Tulak F, Troncale J. Prevalence and characteristics of adolescents patients with co-occurring ADHD and substance dependence. *J Addict Dis*. 2004;23:31–40.
98. Williams RJ, Goodale LA, Shay-Fiddler MA, Gloster SP, Chang SY. Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents. *Am J Addict*. 2004;13:381–389.
99. Ciccone PE. Attempted abuse of concerta. *J Am Acad Child Adolesc Psychiatry*. 2002;41:756.
100. Hechtman L, Abikoff H, Klein RG, et al. Children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment: impact on parental practices. *J Am Acad Child Adolesc Psychiatry*. 2004;43:830–838.
101. Abikoff H, Hechtman L, Klein RG, et al. Social functioning in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment. *J Am Acad Child Adolesc Psychiatry*. 2004;43:820–829.
102. Safren SA, Otto MW, Sprich S, Winett CL, Wilens TE, Biederman J. Cognitive-behavioral therapy for ADHD in medication-treated adults with continued symptoms. *Behav Res Ther*. 2005;43:831–842.
103. Hesslinger B, Tebartz van Elst L, Nyberg E, et al. Psychotherapy of attention deficit hyperactivity disorder in adults—a pilot study using a structured skills training program. *Eur Arch Psychiatry Clin Neurosci*. 2002;252:177–184.
104. Stevenson CS, Whitmont S, Bornholt L, Livesey D, Stevenson RJ. A cognitive remediation programme for adults with Attention Deficit Hyperactivity Disorder. *Aust N Z J Psychiatry*. 2002;36:610–616.
105. Aharonovich E, Hasin DS, Brooks AC, Liu X, Bisaga A, Nunes EV. Cognitive deficits predict low treatment retention in cocaine dependent patients. *Drug Alcohol Depend*. 2006;81:313–322.
106. Conners CK. Clinical use of rating scales in diagnosis and treatment of attention-deficit/hyperactivity disorder. *Pediatr Clin North Am*. 1999;46:857–870.

## TREATMENT STRATEGIES FOR CO-OCCURRING ADHD AND SUBSTANCE USE DISORDER

### Post-test

Please select only one answer for each question. Circle the letter corresponding to the correct answer on the answer form on the back page.

1. Retrospective diagnoses of childhood ADHD in adults made on the basis of self-reports tend to \_\_\_\_\_
  - a. Underdiagnose ADHD
  - b. Overdiagnose ADHD
  - c. Confuse ADHD with bipolar disorder
  - d. Never be done
2. The therapeutic benefit of medications for adult ADHD is more effective when the SUD is ongoing
  - a. TRUE
  - b. FALSE
3. Compared to the community-based National Comorbidity Survey Reports, clinical samples tend to report \_\_\_\_\_ of co-occurring ADHD in individuals with SUD
  - a. A lower rate
  - b. The same rate
  - c. A higher rate
4. Which of the following has NOT been shown in individuals who have both ADHD and SUD compared to SUD cases without ADHD?
  - a. Earlier onset of SUD
  - b. Better response to SUD treatment in adults compared to adolescents
  - c. Reduced likelihood of going into remission
  - d. Longer time to reach remission
5. The effects of atomoxetine in treatment of ADHD are more gradual than those with stimulants
  - a. TRUE
  - b. FALSE
6. Although clinical data are lacking, it is rational to assume that medication misuse in ADHD patients with SUD would be least likely with:
  - a. Immediate-release stimulants
  - b. Intravenous stimulant formulations
  - c. Sustained-release stimulants
  - d. Antidepressants
7. Which of the following is the most rare adverse effect associated with amphetamine treatment of ADHD?
  - a. Emotional lability
  - b. Severe hypertension
  - c. Nausea/vomiting
  - d. Insomnia
8. The mechanism of action of methylphenidate is primarily due to blocking dopamine reuptake in the striatum
  - a. TRUE
  - b. FALSE
9. Which of the following types of antidepressant is contraindicated in patients with SUD?
  - a. Norepinephrine-serotonin reuptake inhibitors
  - b. Dopamine/norepinephrine reuptake inhibitors
  - c. Monoamine oxidate inhibitors
  - d. Tricyclics
10. Most controlled trials have shown that methylphenidate use for ADHD does not reduce cocaine use in those with comorbid cocaine dependence
  - a. TRUE
  - b. FALSE
11. Based on clinical studies, which of the following has been most effective in treatment of cocaine use?
  - a. Methylphenidate
  - b. Dextroamphetamine
  - c. Bromocriptine
  - d. Atomoxetine
12. When treating with stimulants, an important component of managing a patient with co-occurring ADHD and SUD is:
  - a. Polypharmacy
  - b. Sequential rating scale administration
  - c. Assessment of malingering
  - d. Self-reports

## TREATMENT STRATEGIES FOR CO-OCCURRING ADHD AND SUBSTANCE USE DISORDER

Successful completion of the posttest examination (at least 75% correct) and activity evaluation is required to earn a maximum of one (1) **AMA PRA Category 1 Credit™**. Physicians should only claim credit commensurate with the extent of their participation in the activity. Statements of Credit will be awarded upon successful completion of the posttest and evaluation.

To receive a certificate of credit,  
please mail or fax this completed form to:

**Vital Issues in Medicine, A PDI Company**  
**200 Dryden Road, Building #2, Suite 3100**  
**Dresher, PA 19025**  
**Fax: (800) 210-6000**

There is no fee for certificate processing.

### Posttest Answer Form

(Circle the correct answer to each question)

- |              |              |
|--------------|--------------|
| 1. A B C D   | 7. A B       |
| 2. A B       | 8. A B C D E |
| 3. A B C     | 9. A B       |
| 4. A B C D   | 10. A B C D  |
| 5. A B       | 11. A B C D  |
| 6. A B C D E | 12. A B      |

To receive credit, you must answer 9 of the 12 post-test questions correctly, complete all forms, and submit them by January 31, 2008.

### Registration for Credit (please print)

First Name: \_\_\_\_\_

Last Name: \_\_\_\_\_

Degree: ☐ MD ☐ DO ☐ PharmD  
☐ Other: \_\_\_\_\_

Specialty: \_\_\_\_\_

Street Address: \_\_\_\_\_

City: \_\_\_\_\_

State: \_\_\_\_\_

ZIP: \_\_\_\_\_

Telephone #: \_\_\_\_\_

Fax #: \_\_\_\_\_

E-Mail: \_\_\_\_\_

I certify that I have completed this CME activity. The actual amount of time I spent on this activity was:

# of minutes:

Signature: \_\_\_\_\_

Date: \_\_\_\_\_

### Activity Evaluation Form

Please circle the appropriate rating in answer to the questions that follow:

#### Extent to Which this Activity Met the Identified Objectives

Upon completion of this activity, participants should be able to:

1. Identify typical challenges in clinical diagnosis of ADHD in adults with co-occurring SUD.  
Poor 1 2 3 4 5 Outstanding
2. Explain how different types of ADHD pharmacotherapies impact the risks of SUD in specific patients types.  
Poor 1 2 3 4 5 Outstanding
3. Distinguish between primary symptoms and substance-induced symptoms in ADHD patients with SUD.  
Poor 1 2 3 4 5 Outstanding
4. Discuss the pros/cons of non-stimulant medications in patients with ADHD and co-occurring SUD, including second-line medications.  
Poor 1 2 3 4 5 Outstanding
5. Describe treatment scenarios in ADHD that are most likely to lead to SUD, exacerbate ongoing SUD, or minimize risks of SUD.  
Poor 1 2 3 4 5 Outstanding
6. Provide an overview of psychosocial treatments for ADHD and co-occurring SUD that can help optimize long-term treatment effectiveness.  
Poor 1 2 3 4 5 Outstanding

#### Content Relevant to Practice

Not At All Relevant 1 2 3 4 5 Very Relevant

Are there any comments you would like to communicate directly to the authors?  
\_\_\_\_\_  
\_\_\_\_\_

### Overall Effectiveness of the Activity

1. Objectives were related to overall purpose/goal(s) of activity.  
Poor 1 2 3 4 5 Outstanding
2. Related to my practice needs.  
Poor 1 2 3 4 5 Outstanding
3. Will influence how I practice.  
Poor 1 2 3 4 5 Outstanding
4. Will help me improve patient care.  
Poor 1 2 3 4 5 Outstanding
5. Stimulated my intellectual curiosity.  
Poor 1 2 3 4 5 Outstanding
6. Overall, the activity met my expectations.  
Poor 1 2 3 4 5 Outstanding

Was the information in this activity presented in an unbiased manner?

☐ YES ☐ NO

Will the information presented cause you to make any changes in your practice?

☐ YES ☐ NO

If YES, please describe any change(s) you plan to make in your practice as a result of this activity.  
\_\_\_\_\_  
\_\_\_\_\_

How committed to making these changes?

Not At All Committed 1 2 3 4 5 Very Committed

Additional comments about this activity?  
\_\_\_\_\_  
\_\_\_\_\_

Do you feel future activities on this subject are necessary and/or important to your practice?

☐ YES ☐ NO

Please list any other topics that would be of interest to you for future educational activities.  
\_\_\_\_\_  
\_\_\_\_\_

Copyright of *American Journal on Addictions* is the property of Taylor & Francis Ltd and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use.